Cláudio Maia

Prof. Dr. Cláudio Maia

Faculty of Health Sciences, University of Beira Interior, 6201-506 Covilha, Portugal
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2012 in Cell and tissue research
Verified
Journal Article
Closed access
PDF file
AMA. C. Mamede
A. C. Mamede
MCMaria João Carvalho
Maria João Carvalho
Ana Margarida AbrantesAna Margarida Abrantes
Ana Margarida Abrantes
Mafalda LaranjoMafalda Laranjo
Mafalda Laranjo
Cláudio MaiaCláudio Maia
Cláudio Maia
Maria Filomena BotelhoMaria Filomena Botelho
Maria Filomena Botelho

1 May 2012 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
IGInês M. Gomes
Inês M. Gomes
Cláudio MaiaCláudio Maia
Cláudio Maia
Cecília R. SantosCecília R. Santos
Cecília R. Santos
The human 6-transmembrane epithelial antigen of prostate (STEAP) family comprises STEAP1, STEAP2, STEAP3, and STEAP4. All of these proteins are unique to mammals and share an innate activity as metalloreductases, indicating their importance in metal metabolism. Overall, they participate in a wide range of biologic processes, such as molecular trafficking in the endocytic and exocytic pathways and control of cell proliferation and apoptosis. STEAP1 and STEAP2 are overexpressed in several types of human cancers, namely prostate, bladder, colon, pancreas, ovary, testis, breast, cervix, and Ewing sarcoma, but their clinical significance and role in cancer cells are not clear. Still, their localization in the cell membrane and differential expression in normal and cancer tissues make STEAP proteins potential candidates as biomarkers of several cancers, as well as potential targets for new immunotherapeutic strategies for disease attenuation or treatment. This review brings together the current knowledge about each STEAP protein, giving an overview of the roles of this family of proteins in human physiology and disease, and analyzes their potential as immunotherapeutic agents in cancer research. Mol Cancer Res; 10(5); 573–87. ©2012 AACR.

1 November 2012 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
CVCátia V. Vaz
Cátia V. Vaz
Marco AlvesMarco Alves
Marco Alves
RMRicardo Marques
Ricardo Marques
Paula MoreiraPaula Moreira
Paula Moreira
Pedro F. OliveiraPedro F. Oliveira
Pedro F. Oliveira
Silvia SocorroSilvia Socorro
Silvia Socorro

6 June 2015 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
CVCátia V. Vaz
Cátia V. Vaz
RMRicardo Marques
Ricardo Marques
Marco AlvesMarco Alves
Marco Alves
Pedro F. OliveiraPedro F. Oliveira
Pedro F. Oliveira
ECEduardo Brites Cavaco
Eduardo Brites Cavaco
Silvia SocorroSilvia Socorro
Silvia Socorro

1 January 2014 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
IGInês M. Gomes
Inês M. Gomes
PAPatrícia Arinto
Patrícia Arinto
CLCarlos Lopes
Carlos Lopes
Cecília R. SantosCecília R. Santos
Cecília R. Santos
Cláudio MaiaCláudio Maia
Cláudio Maia

14 August 2014 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
Sofia ReisSofia Reis
Sofia Reis
BGBeatriz Gullón
Beatriz Gullón
PGPatricia Gullón
Patricia Gullón
Susana FerreiraSusana Ferreira
Susana Ferreira
Cláudio MaiaCláudio Maia
Cláudio Maia
NANissreen Abu-Ghannam
Nissreen Abu-Ghannam